Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes drug tame chronic heart failure? a Real-World study investigates

NCT ID NCT05236673

Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study observes Korean adults with chronic heart failure (NYHA class II-IV) who are starting Jardiance (empagliflozin) for the first time. The main goal is to track the drug's safety in everyday clinical practice, including any side effects or serious reactions. Researchers will also look at whether the drug reduces hospitalizations for heart failure. This is an observational study, meaning participants receive standard care and no experimental treatment is given.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
empagliflozin (Jardiance), a 10mg tablet taken by mouth
What this could lead to
If this study shows that empagliflozin is safe and effective in Korean patients with chronic heart failure, it could support its continued use in routine care for this population.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. The results may be influenced by other factors, and the safety monitoring may not capture all rare or long-term side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

676 people

The number who actually took part.

Started

Jul 2022

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with chronic heart failure (New York Heart Association (NYHA) class II-IV) in Korea.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Patients who have started at first time on Jardiance® in accordance with the approved label in Korea for heart failure (HF) * Chronic heart failure (New York Heart Association (NYHA) class II-IV) * Age ≥ 19 years at enrolment * Patients who have signed on the data release consent form Exclusion criteria: * Patients with previous exposure to Jardiance® * Known allergy or hypersensitivity to active ingredients empagliflozin or to any of the excipients * Patients with type 1 diabetes or with prior history of diabetic ketoacidosis (DKA) * Patient with renal impairment with estimated Glomerular Filtration Rate (eGFR) \< 20 mL/min/1.73 m² * Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption * Patient who are pregnant or are nursing or who plan to become pregnant while in the trial * Patients for whom empagliflozin is contraindicated according local label of Jardiance®

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Chonnam National University Hospital)

    Gwangju, 61469, South Korea

  • Chungnam National University Hospital

    Daejeon, 35015, South Korea

  • Dongguk University Medical Center

    Goyang-si, Gyeonggi-do, 10326, South Korea

  • Hallym University Medical Center

    Anyang-si, Gyeonggi-do, 14068, South Korea

  • Inje University Busan Paik Hospital

    Busan, 47392, South Korea

  • Inje University Haeundae Paik Hospital

    Busan, 48108, South Korea

  • Inje University Ilsan Paik Hospital

    Goyang-si, Gyeonggi-do, 10380, South Korea

  • Jeonbuk National University Hospital

    Jeonju-si, Jeollabuk-do, 54907, South Korea

  • Kangwon National University Hospital

    Chuncheon-si, Gangwon-do, 24289, South Korea

  • Korea University Anam Hospital

    Seoul, 02841, South Korea

  • Kyungpook National University Hospital

    Daegu, 41944, South Korea

  • Pusan National University Hospital

    Busan, 49241, South Korea

  • Pusan National University Yangsan Hospital

    Busan, 50612, South Korea

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Seoul National University Boramae Medical Center

    Seoul, 07061, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • The Catholic University of Korea, Seoul ST. Mary's Hospital

    Seoul, 06591, South Korea

  • The Catholic University of Korea, Uijeongbu ST. Mary's Hospital

    Uijeongbu-si, Gyeonggi-do, 11765, South Korea

  • VHS Medical Center

    Seoul, 05368, South Korea

  • Yeungnam University Medical Center

    Daegu, 42415, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.